ViiV HEALTHCARE ANNOUNCES SUPPORT FOR COMMUNITY-BASED ORGANIZATIONS WITH NEW MONKEYPOX EMERGENCY RESPONSE FUND IN THE US
Media Contacts
For US-specific media inquiries, email:
audrey.x.abernathy@viivhealthcare.com
OR call +1 919 605 4521
For our corporate press office:
call +44 7557 290 420
Durham, NC, August 10, 2022 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced an emergency response fund for community-based organizations that are responding to the monkeypox virus outbreak, which last week the US Department of Health and Human Services declared a public health emergency as the US outbreak has grown into the largest in the world.1
As monkeypox cases surge across the US and disproportionately affect LGBTQ communities, particularly men who have sex with men, and people living with HIV, ViiV Healthcare’s Positive Action Monkeypox Emergency Response Fund will make available $500,000 in grants to help community-based organizations who serve people living with HIV respond to the emerging Monkeypox public health crisis.
Lynn Baxter, Head of ViiV Healthcare North America, said: “We see again the critical role that community-based organizations play in responding to public health emergencies and pandemics. Our Monkeypox Emergency Response Fund is designed to help frontline, grassroots organizations respond to the monkeypox emergency in the US by providing much needed financial support to continue their work and meet the urgent need for monkeypox prevention, screening and education. For the past 30 years, we have worked alongside community-based organizations to address the evolving needs of the HIV community and this fund is another example of our ongoing support.”
ViiV Healthcare’s Monkeypox Emergency Response Fund will support US community-based organizations. Eligible US organizations should submit applications via the online grants portal at https://viivhealthcare.fluxx.io/ for up to $50,000 to support increased outreach, education, testing, and access to prevention and care for monkeypox in community settings. Funding cannot be used for the provision of medical care or the salaries of licensed medical professionals. Applications may be submitted on a rolling basis between August 10 and September 30, 2022. For more information, see the Request for Proposals here.
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined as a shareholder in October 2012. The company’s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.
For more information on the company, its management, portfolio, pipeline, and commitment, please visit www.viivhealthcare.com.
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com/company.
| ViiV Healthcare enquiries: |
||
| Media enquiries: |
Audrey Abernathy |
+1 919 605 4521 (North Carolina) |
| GSK enquiries: | ||
| Media enquiries: |
Kathleen Quinn |
+1 202 603 5003 (Washington DC) |
| Tim Foley | +44 (0) 20 8047 5502 (London) |
|
Dan Smith |
+44 (0) 20 8047 5502 (London) |
|
| Analyst/Investor enquiries: |
Nick Stone |
+44 (0) 7717 618834 (London) |
| James Dodwell |
+44 (0) 20 8047 2406 (London) |
|
| Mick Readey |
+44 (0) 7990 339653 (London) |
|
| Josh Williams |
+44 (0) 7385 415719 (London) |
|
| Jeff McLaughlin |
+1 215 751 7002 (Philadelphia) |
|
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2021, GSK’s Q2 Results for 2022 and any impacts of the COVID-19 pandemic.
Registered in England & Wales:
GSK plc ViiV Healthcare Limited
No. 3888792 No. 06876960
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
- US Centers for Disease Control and Prevention.2022 Monkeypox Outbreak Global Map available at 2022 Monkeypox Outbreak Global Map | Monkeypox | Poxvirus | CDC. Accessed August 9, 2022.
